These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 31163986)

  • 1. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
    Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Waijer SW; Xie D; Inzucchi SE; Zinman B; Koitka-Weber A; Mattheus M; von Eynatten M; Inker LA; Wanner C; Heerspink HJL
    J Am Heart Assoc; 2020 Sep; 9(18):e016976. PubMed ID: 32893717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
    Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.
    Ferreira JP; Kraus BJ; Zwiener I; Lauer S; Zinman B; Fitchett DH; Koitka-Weber A; George JT; Ofstad AP; Wanner C; Zannad F
    J Am Heart Assoc; 2021 Apr; 10(7):e020053. PubMed ID: 33754809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
    J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
    Zannad F; Ferreira JP; Pocock SJ; Zeller C; Anker SD; Butler J; Filippatos G; Hauske SJ; Brueckmann M; Pfarr E; Schnee J; Wanner C; Packer M
    Circulation; 2021 Jan; 143(4):310-321. PubMed ID: 33095032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
    Wanner C; Iliev H; Duarte N; Schueler E; Soares AR; Thanam V; Pfarr E
    Adv Ther; 2024 Jul; 41(7):2826-2844. PubMed ID: 38771475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
    Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
    Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
    Ferreira JP; Verma S; Fitchett D; Ofstad AP; Lauer S; Zwiener I; George J; Wanner C; Zinman B; Inzucchi SE
    Cardiovasc Diabetol; 2020 Nov; 19(1):200. PubMed ID: 33243221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
    Böhm M; Fitchett D; Ofstad AP; Brueckmann M; Kaspers S; George JT; Zwiener I; Zinman B; Wanner C; Marx N; Mancia G; Anker SD; Mahfoud F
    J Hypertens; 2020 Sep; 38(9):1829-1840. PubMed ID: 32618884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
    McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
    Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
    Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
    Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.